Dosing of single-shot pulsed field ablation systems: A systematic review of efficacy and safety balance.

Heart RhythmMay 25, 2026 (epub)
Clinical ResearchCardiology

Isabelle N Bax, Roos E Bolhuis, Marisa van der Graaf et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy and safety of single-shot pulsed field ablation (PFA) systems for pulmonary vein isolation in atrial fibrillation, analyzing 47 primary studies. The review found that all PFA systems achieved nearly 100% acute pulmonary vein isolation. However, complications such as acute kidney injury and myocardial injury were associated with specific catheter types and increased applications.

Key findings

  • All PFA systems reported almost 100% acute pulmonary vein isolation.
  • Acute kidney injury occurred with pentaspline (n = 39 of 1307) and variable-loop catheters (n = 4 of 122).
  • 6-12 months of arrhythmia-free survival was 55%-88% for multispline and circular catheters, and 77%-88% for spherical catheters.

Why it matters

Understanding the efficacy and safety profile of pulsed field ablation systems is crucial for clinicians managing atrial fibrillation, as it informs treatment decisions and patient counseling regarding potential complications.

What to keep in mind

The review highlights the heterogeneity of PFA systems, making direct comparisons challenging.

Source

Published in Heart Rhythm. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.